

# WEST Search History

DATE: Thursday, July 11, 2002

| <u>Set</u><br><u>Name</u> | <u>Query</u>   | <u>Hit</u><br><u>Count</u> | <u>Set</u><br><u>Name</u><br>result set |
|---------------------------|--|----------------------------|---|
| side by<br>side           |  |                            |   |
|                           | <i>DB=USPT; PLUR=YES; OP=AND</i>   |                            |   |
| L1                        | d2l2 or d2-l2 or d-2-l-2   | 5                          | L1                                      |
|                           | <i>DB=JPAB,EPAB,DWPI; PLUR=YES; OP=AND</i>   |                            |   |
| L2                        | d2l2 or d2-l2 or d-2-l-2   | 5                          | L2                                      |
|                           | <i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES;<br/>OP=AND</i>   |                            |   |
| L3                        | (transmembran\$ or translocat\$ or endocyto\$ or<br>trans-membran\$ or trans-locat\$ or<br>endo-cyto\$).clm.   | 1282                       | L3                                      |
|                           | <i>DB=PGPB; PLUR=YES; OP=AND</i>   |                            |   |
| L4                        | (transmembran\$ or translocat\$ or endocyto\$ or<br>trans-membran\$ or trans-locat\$ or<br>endo-cyto\$).clm.   | 170                        | L4                                      |
| L5                        | L3 not l4  | 0                          | L5                                      |
| L6                        | l3 and (mutant or mutation or mutagen\$ or<br>alter\$ or mutants or mutations or inactivat\$ or<br>alterat\$ or altered or alters or changed or<br>changes or deletion or substitution ).clm. and l3 | 63                         | L6                                      |
|                           | <i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES;<br/>OP=AND</i>   |                            |   |
| L7                        | l3 and (mutant or mutation or mutagen\$ or<br>alter\$ or mutants or mutations or inactivat\$ or<br>alterat\$ or altered or alters or changed or<br>changes or deletion or substitution ).clm. and l3 | 329                        | L7                                      |

|     |  |      |     |
|-----|--|------|-----|
| L8  | l3 and (mutant or mutation or mutagen\$ or<br>alter\$ or mutants or mutations or inactivat\$ or<br>alterat\$ or altered or alters or changed or<br>changes or deletion or substitution ).clm. and l3 | 329  | L8  |
| L9  | l8 and ((beta or b or binary) same (subunit or<br>sub-unit or moiety or domain)).clm.  | 44   | L9  |
| L10 | pore.clm. same (\$toxin or toxin\$).clm. and l3  | 2    | L10 |
| L11 | (pore or chanell) near2 form\$   | 5546 | L11 |
| L12 | (pore or chanell) near2 form\$   | 5546 | L12 |
| L13 | L11 same (moiety or domain or subunit or<br>sub-unit)  | 60   | L13 |
| L14 | ('6329156')[ABPN1,NRPN,PN,WKU]   | 2    | L14 |
| L15 | ('6329156')[ABPN1,NRPN,PN,WKU]   | 2    | L15 |

END OF SEARCH HISTORY

**WEST****Search Results - Record(s) 1 through 2 of 2 returned.**

L29: Entry 1 of 2

File: USPT

Dec 11, 2001

US-PAT-NO: 6329156

DOCUMENT-IDENTIFIER: US 6329156 B1

TITLE: Method for screening inhibitors of the toxicity of Bacillus anthracis

DATE-ISSUED: December 11, 2001

US-CL-CURRENT: 435/7.21, 435/4, 435/6, 435/7.2, 435/7.32, 436/172, 436/544, 436/546INT-CL: [7] G01 N 33/567, G01 N 33/554, G01 N 33/532, G01 N 33/533

L29: Entry 2 of 2

File: DWPI

Dec 11, 2001

DERWENT-ACC-NO: 2002-121130

ABSTRACTED-PUB-NO: US 6329156B

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Screening Bacillus anthracis toxicity inhibitor (T) by generating recombinant protective antigen 32, comparing fluorescence of cells contacted with PA32-fluorescent marker fusion protein before, after contact with T

INT-CL (IPC): G01 N 33/532, G01 N 33/533, G01 N 33/554, G01 N 33/567

Derwent-CL (DC): B04, C06, D16, S03

CPI Codes: B04-C01G; B04-E03F; B04-F0100E; B04-N04A0E; B11-C08E1; B11-C09; B12-K04E; B14-L01;

B14-L06; C04-C01G; C04-E03F; C04-F0100E; C04-N04A0E; C11-C08E1; C11-C09; C12-K04E; C14-A01;

C14-L01; C14-L06; D05-C12; D05-H08; D05-H09; D05-H12A; D05-H12C; D05-H14; D05-H17A6; D05-H17C;

D05-H18;

EPI Codes: S03-E14H; S03-E14H4;

**WEST**

Generate Collection

Print

L27: Entry 12 of 60

File: USPT

Dec 11, 2001

DOCUMENT-IDENTIFIER: US 6329156 B1

TITLE: Method for screening inhibitors of the toxicity of Bacillus anthracis

Detailed Description Paragraph Right (22):

PA32 offers several advantages over the current human vaccine. The receptor binding region is a higher proportion of the total immunogenic surface, suggesting a higher proportion of antibodies will be neutralizing. E. coli expression and IMAC purification are extremely efficient. Being structurally truncated, the PA32 molecule is unable to interact with toxin A subunits and so is non-toxic, and this PA fragment is unable to form pores due to absence of the D2L2 loop of domain 2.

**WEST**

Generate Collection

Print

L27: Entry 24 of 60

File: USPT

Jan 30, 2001

DOCUMENT-IDENTIFIER: US 6180356 B1

TITLE: Membrane pore inhibiting agents for treating infection

Detailed Description Paragraph Right (44):

Pore formation in the absence of the catalytic domain of the toxin was studied using the single domain of the toxin denoted the transmembrane domain or T domain. The T domain of diphtheria toxin lacks both the catalytic domain of the toxin (which contains the catalytic site) and the receptor binding domain of the toxin. The T domain has been shown to form pores in membranes similar to the pores observed for the entire toxin molecule. See, for example, Silverman J. A. et al. J. Membrane Biol. 137, 17-28 (1994).